Genus plc (GENSF)
USD 25.1
(0.0%)
USD 25.1
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 178.7 Million USD | -43.02% |
| 2023 | 313.64 Million USD | 20.81% |
| 2022 | 259.6 Million USD | -15.01% |
| 2021 | 305.43 Million USD | 24.41% |
| 2020 | 245.51 Million USD | 12.75% |
| 2019 | 217.75 Million USD | -2.35% |
| 2018 | 222.99 Million GBP | 7.29% |
| 2017 | 207.83 Million GBP | 8.95% |
| 2016 | 190.76 Million GBP | 20.66% |
| 2015 | 158.1 Million GBP | 22.27% |
| 2014 | 129.3 Million GBP | 8.38% |
| 2013 | 119.3 Million GBP | -22.73% |
| 2012 | 154.4 Million GBP | -20.17% |
| 2011 | 193.4 Million GBP | 7.21% |
| 2010 | 180.4 Million GBP | 13.82% |
| 2009 | 158.5 Million GBP | 11.38% |
| 2008 | 142.3 Million GBP | 2.23% |
| 2007 | 139.2 Million GBP | -30.82% |
| 2006 | 201.2 Million GBP | 76.64% |
| 2005 | 113.9 Million GBP | -38.0% |
| 2004 | 183.71 Million GBP | 6.32% |
| 2003 | 172.79 Million GBP | 7.71% |
| 2002 | 160.42 Million GBP | -1.51% |
| 2001 | 162.87 Million GBP | 21.79% |
| 2000 | 133.73 Million GBP | 133.78% |
| 1999 | 57.2 Million GBP | 20.32% |
| 1998 | 47.54 Million GBP | 1.96% |
| 1997 | 46.63 Million GBP | -2.64% |
| 1996 | 47.89 Million GBP | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 166.8 Million GBP | -22.91% |
| 2024 Q2 | 166.8 Million USD | 0.0% |
| 2024 FY | 845.56 Million USD | 169.59% |
| 2024 Q4 | 423.79 Million USD | 0.0% |
| 2023 Q2 | 175.1 Million USD | 0.0% |
| 2023 Q1 | 175.1 Million GBP | 734.42% |
| 2023 Q3 | -44.8 Million GBP | -125.59% |
| 2023 Q4 | 216.37 Million USD | 582.99% |
| 2023 FY | 313.64 Million USD | 20.81% |
| 2022 Q1 | 140.6 Million GBP | 625.61% |
| 2022 FY | 259.6 Million USD | -15.01% |
| 2022 Q3 | -27.6 Million GBP | -119.63% |
| 2022 Q2 | 140.6 Million USD | 0.0% |
| 2022 Q4 | -27.6 Million USD | 0.0% |
| 2021 FY | 305.43 Million USD | 24.41% |
| 2021 Q2 | 142.85 Million USD | 0.0% |
| 2021 Q1 | 142.85 Million GBP | 583.42% |
| 2021 Q4 | -26.75 Million USD | 0.0% |
| 2021 Q3 | -26.75 Million GBP | -118.73% |
| 2020 Q2 | 135.35 Million USD | 0.0% |
| 2020 Q4 | -29.55 Million USD | 0.0% |
| 2020 FY | 245.51 Million USD | 12.75% |
| 2020 Q1 | 135.35 Million GBP | 7619.44% |
| 2020 Q3 | -29.55 Million GBP | -121.83% |
| 2019 Q1 | 94.8 Million GBP | 2230.34% |
| 2019 Q3 | -1.8 Million GBP | -101.9% |
| 2019 FY | 217.75 Million USD | -2.35% |
| 2019 Q4 | -1.8 Million USD | 0.0% |
| 2019 Q2 | 94.8 Million GBP | 0.0% |
| 2018 Q1 | 95.8 Million GBP | 1737.61% |
| 2018 Q2 | 95.8 Million GBP | 0.0% |
| 2018 FY | 222.99 Million GBP | 7.29% |
| 2018 Q3 | -4.45 Million GBP | -104.65% |
| 2018 Q4 | -4.45 Million GBP | 0.0% |
| 2017 Q4 | -5.85 Million GBP | 0.0% |
| 2017 FY | 207.83 Million GBP | 8.95% |
| 2017 Q1 | 91.45 Million GBP | 573.83% |
| 2017 Q2 | 91.45 Million GBP | 0.0% |
| 2017 Q3 | -5.85 Million GBP | -106.4% |
| 2016 FY | 190.76 Million GBP | 20.66% |
| 2016 Q4 | -19.3 Million GBP | 0.0% |
| 2016 Q3 | -19.3 Million GBP | -120.5% |
| 2016 Q2 | 94.15 Million GBP | 0.0% |
| 2016 Q1 | 94.15 Million GBP | 225.7% |
| 2015 FY | 158.1 Million GBP | 22.27% |
| 2015 Q3 | -74.9 Million GBP | -175.47% |
| 2015 Q1 | 99.25 Million GBP | 1755.14% |
| 2015 Q2 | 99.25 Million GBP | 0.0% |
| 2015 Q4 | -74.9 Million GBP | 0.0% |
| 2014 Q4 | 5.35 Million GBP | 0.0% |
| 2014 FY | 129.3 Million GBP | 8.38% |
| 2014 Q3 | 5.35 Million GBP | -52.02% |
| 2014 Q2 | 11.15 Million GBP | 0.0% |
| 2014 Q1 | 11.15 Million GBP | 156.03% |
| 2013 Q2 | - GBP | 0.0% |
| 2013 FY | 119.3 Million GBP | -22.73% |
| 2013 Q4 | -19.9 Million GBP | 0.0% |
| 2013 Q3 | -19.9 Million GBP | 0.0% |
| 2012 Q2 | - GBP | 0.0% |
| 2012 FY | 154.4 Million GBP | -20.17% |
| 2011 FY | 193.4 Million GBP | 7.21% |
| 2011 Q2 | - GBP | 0.0% |
| 2010 FY | 180.4 Million GBP | 13.82% |
| 2010 Q2 | - GBP | 0.0% |
| 2009 FY | 158.5 Million GBP | 11.38% |
| 2009 Q2 | - GBP | 0.0% |
| 2008 Q2 | - GBP | 0.0% |
| 2008 FY | 142.3 Million GBP | 2.23% |
| 2007 Q2 | - GBP | 0.0% |
| 2007 FY | 139.2 Million GBP | -30.82% |
| 2006 FY | 201.2 Million GBP | 76.64% |
| 2006 Q1 | - GBP | 0.0% |
| 2005 FY | 113.9 Million GBP | -38.0% |
| 2005 Q1 | - GBP | 0.0% |
| 2004 Q1 | - GBP | 0.0% |
| 2004 FY | 183.71 Million GBP | 6.32% |
| 2003 FY | 172.79 Million GBP | 7.71% |
| 2002 FY | 160.42 Million GBP | -1.51% |
| 2001 FY | 162.87 Million GBP | 21.79% |
| 2000 FY | 133.73 Million GBP | 133.78% |
| 1999 FY | 57.2 Million GBP | 20.32% |
| 1998 FY | 47.54 Million GBP | 1.96% |
| 1997 FY | 46.63 Million GBP | -2.64% |
| 1996 FY | 47.89 Million GBP | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 7326873.268% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -1426.568% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 56029.917% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -50.032% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 792.689% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 370393.624% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 143921.78% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -1091.413% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -5760699.484% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -1724.586% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -271778.043% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 523379.649% |
| Mesoblast Limited | -35.16 Million USD | 608.132% |
| Marizyme, Inc. | 457.7 Thousand USD | -38942.871% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 18.811% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -287078.993% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -43467.832% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 1624645.455% |
| ContraFect Corporation | -154 Thousand USD | 116138.961% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 357500.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -232700.511% |
| IMV Inc. | -962.29 Thousand USD | 18670.131% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 46216.01% |
| MultiCell Technologies, Inc. | 49.32 USD | -362327556.123% |
| ONE Bio Corp. | 20.12 Million USD | -787.931% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -343.81% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -365339.673% |
| Q BioMed Inc. | -8988.00 USD | 1988306.498% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -532.454% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 1158684.025% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -302.86% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 15753.853% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -255185.714% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 3608742.973% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -127088.612% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 183353.858% |
| GB Sciences, Inc. | -624.00 USD | 28637920.513% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 207823.067% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 97.637% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 85913561.538% |
| Enzolytics Inc. | 30.7 Thousand USD | -581833.047% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -36941.413% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 83.879% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 34832.075% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -28844.709% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 56.367% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 2017941.012% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 213221.206% |
| Kadimastem Ltd | -630.13 Thousand USD | 28458.867% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -17987.392% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -1759.328% |
| BioStem Technologies, Inc. | 15.42 Million USD | -1058.52% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 1510028.179% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -101112.053% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -101112.053% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -13067.367% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 616306.897% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -39607.317% |
| SYBLEU INC | 11.69 Thousand USD | -1527772.777% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -3778.038% |
| Bioxytran, Inc. | -8285.00 USD | 2157010.078% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 48008.847% |
| Neutra Corp. | 14.33 Thousand USD | -1246499.233% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 218026.829% |
| PureTech Health plc | -1.6 Million USD | 11247.848% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 17947.94% |
| IXICO plc | 3.27 Million USD | -5364.832% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 25849.28% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 10077.666% |
| CSL Limited | 7.7 Billion USD | 97.681% |
| Cellectis S.A. | 18 Thousand USD | -992677.778% |